All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Abstract The 11th Acromegaly Consensus Conference in April 2017 was convened to
update recommendations on therapeutic outcomes for patients with acromegaly. Consensus …

Pituitary-Tumor Endocrinopathies Pituitary adenomas account for about 15% of intracranial
tumors. Clinical manifestations of disease reflect the oversecretion of the involved hormone …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Abstract Design Valid data on acromegaly incidence, complications and mortality are
scarce. The Danish Health Care System enables nationwide studies with complete follow-up …

Acromegaly is typically caused by a growth hormone–secreting pituitary adenoma, driving
excess secretion of insulin-like growth factor 1. Acromegaly may result in a variety of …

Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

Acromegaly is characterized by increased release of growth hormone and, consequently,
insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …